Joanne E Sordillo1, Rachel S Kelly2, Sharon M Lutz1, Jessica Lasky-Su2, Ann Chen Wu3. 1. PrecisiOn Medicine Translational Research (PROMoTeR) Center, Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health Care, MA, Boston, USA. 2. Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 3. PrecisiOn Medicine Translational Research (PROMoTeR) Center, Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health Care, MA, Boston, USA. ann.wu@childrens.harvard.edu.
Abstract
PURPOSE OF REVIEW: Several genome-wide association studies (GWASs) of bronchodilator response (BDR) to albuterol have been published over the past decade. This review describes current knowledge gaps, including pharmacogenetic studies of albuterol response in minority populations, effect modification of pharmacogenetic associations by age, and relevance of BDR phenotype characterization to pharmacogenetic findings. New approaches, such as leveraging additional "omics" data to focus pharmacogenetic interrogation, as well as developing polygenic risk scores in asthma treatment responses, are also discussed. RECENT FINDINGS: Recent pharmacogenetic studies of albuterol response in minority populations have identified genetic polymorphisms in loci (DNAH5, NFKB1, PLCB1, ADAMTS3, COX18, and PRKG1), that are associated with BDR. Additional studies are needed to replicate these findings. Modification of the pharmacogenetic associations for SPATS2L and ASB3 polymorphisms by age has also been published. Evidence from metabolomic and epigenomic studies of BDR may point to new pharmacogenetic targets. Lastly, a polygenic risk score for response to albuterol has been developed but requires validation in additional cohorts. In order to expand our knowledge of pharmacogenetics of BDR, additional studies in minority populations are needed. Consideration of effect modification by age and leverage of other "omics" data beyond genomics may also help uncover novel pharmacogenetic loci for use in precision medicine for asthma treatment.
PURPOSE OF REVIEW: Several genome-wide association studies (GWASs) of bronchodilator response (BDR) to albuterol have been published over the past decade. This review describes current knowledge gaps, including pharmacogenetic studies of albuterol response in minority populations, effect modification of pharmacogenetic associations by age, and relevance of BDR phenotype characterization to pharmacogenetic findings. New approaches, such as leveraging additional "omics" data to focus pharmacogenetic interrogation, as well as developing polygenic risk scores in asthma treatment responses, are also discussed. RECENT FINDINGS: Recent pharmacogenetic studies of albuterol response in minority populations have identified genetic polymorphisms in loci (DNAH5, NFKB1, PLCB1, ADAMTS3, COX18, and PRKG1), that are associated with BDR. Additional studies are needed to replicate these findings. Modification of the pharmacogenetic associations for SPATS2L and ASB3 polymorphisms by age has also been published. Evidence from metabolomic and epigenomic studies of BDR may point to new pharmacogenetic targets. Lastly, a polygenic risk score for response to albuterol has been developed but requires validation in additional cohorts. In order to expand our knowledge of pharmacogenetics of BDR, additional studies in minority populations are needed. Consideration of effect modification by age and leverage of other "omics" data beyond genomics may also help uncover novel pharmacogenetic loci for use in precision medicine for asthma treatment.
Authors: H J Waalkens; P J Merkus; E E van Essen-Zandvliet; P L Brand; J Gerritsen; E J Duiverman; K F Kerrebijn; K K Knol; P H Quanjer Journal: Eur Respir J Date: 1993-05 Impact factor: 16.671
Authors: Lyle J Palmer; Juan C Celedón; Harold A Chapman; Frank E Speizer; Scott T Weiss; Edwin K Silverman Journal: Hum Mol Genet Date: 2003-05-15 Impact factor: 6.150
Authors: Augusto A Litonjua; Jessica Lasky-Su; Kady Schneiter; Kelan G Tantisira; Ross Lazarus; Barbara Klanderman; John J Lima; Charles G Irvin; Stephen P Peters; John P Hanrahan; Stephen B Liggett; Gregory A Hawkins; Deborah A Meyers; Eugene R Bleecker; Christoph Lange; Scott T Weiss Journal: Am J Respir Crit Care Med Date: 2008-07-10 Impact factor: 21.405
Authors: Brian J Lipworth; Kaninika Basu; Helen P Donald; Roger Tavendale; Donald F Macgregor; Simon A Ogston; Colin N A Palmer; Somnath Mukhopadhyay Journal: Clin Sci (Lond) Date: 2013-04 Impact factor: 6.124
Authors: Melissa L Spear; Donglei Hu; Maria Pino-Yanes; Scott Huntsman; Celeste Eng; Albert M Levin; Victor E Ortega; Marquitta J White; Meghan E McGarry; Neeta Thakur; Joshua Galanter; Angel C Y Mak; Sam S Oh; Elizabeth Ampleford; Stephen P Peters; Adam Davis; Rajesh Kumar; Harold J Farber; Kelley Meade; Pedro C Avila; Denise Serebrisky; Michael A Lenoir; Emerita Brigino-Buenaventura; William Rodriguez Cintron; Shannon M Thyne; Jose R Rodriguez-Santana; Jean G Ford; Rocio Chapela; Andrés Moreno Estrada; Karla Sandoval; Max A Seibold; Cheryl A Winkler; Eugene R Bleecker; Deborah A Myers; L Keoki Williams; Ryan D Hernandez; Dara G Torgerson; Esteban G Burchard Journal: Pharmacogenomics J Date: 2018-09-12 Impact factor: 3.550
Authors: Joanne E Sordillo; Sharon M Lutz; Rachel S Kelly; Michael J McGeachie; Amber Dahlin; Kelan Tantisira; Clary Clish; Jessica Lasky-Su; Ann Chen Wu Journal: Front Med (Lausanne) Date: 2020-02-14
Authors: Amber Dahlin; Joanne E Sordillo; Michael McGeachie; Rachel S Kelly; Kelan G Tantisira; Sharon M Lutz; Jessica Lasky-Su; Ann Chen Wu Journal: PLoS One Date: 2020-03-02 Impact factor: 3.240